Literature DB >> 30624371

Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension.

Joshua G Woolstenhulme1, Andrew A Guccione, Jeffrey E Herrick, John P Collins, Steven D Nathan, Leighton Chan, Randall E Keyser.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is a chronic debilitating illness. The effects of vigorous aerobic exercise training (AET) on heart function in PAH are poorly understood.
METHODS: Eighteen women with PAH (aged 56.2 ± 8.8 yr, body mass index: 28.8 ± 7.3 kg/m) underwent 10 wk of vigorous AET. Cardiac function was observed at rest and peak exercise using bioelectrical impedance cardiography before and after the AET. Cardiac function was observed in a small PAH subset (n = 7) for 10 wk before beginning the AET. A cohort of sedentary women (n = 19) served as healthy controls.
RESULTS: Left ventricular ejection fraction (48 ± 9.2 vs 61.5 ± 13.3%, P = .034) and the systemic vascular resistance index (2258 ± 419.1 vs 2939 ± 962.4 dyn·sec/cm·m, P = .008) were lower at supine rest in the baseline PAH group versus the healthy group, as were peak exercise heart rate (140 ± 13.3 vs 170 ± 13.8 beats/min, P < .001) and systemic vascular resistance index (828 ± 141.1 vs 824 ± 300.9 dyn·sec/cm·m, P = .050) after controlling for age and heart rate. Systemic vascular resistance index measured at peak exercise decreased in the PAH group after AET (828 ± 141.1 vs 766 ± 139.6 dyn·sec/cm·m, P = .020). Left ventricular early diastolic filling ratio worsened in the PAH subset prior to AET (95.9 ± 19.4 vs 76.2 ± 18.9%, P = .043) and remained unchanged after AET.
CONCLUSION: Vigorous AET was not associated with significant declines in left ventricular systolic or diastolic function in women with PAH. Aerobic exercise training may be beneficial for reducing afterload and may preserve left ventricular diastolic function.

Entities:  

Mesh:

Year:  2019        PMID: 30624371      PMCID: PMC6452473          DOI: 10.1097/HCR.0000000000000397

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  48 in total

Review 1.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 2.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.

Authors:  Harm J Bogaard; Kohtaro Abe; Anton Vonk Noordegraaf; Norbert F Voelkel
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

Review 3.  Public health recommendations for physical activity in the prevention of type 2 diabetes mellitus.

Authors:  Estelle Victoria Lambert; Fiona Bull
Journal:  Med Sport Sci       Date:  2014-09-09

4.  Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.

Authors:  Derliz Mereles; Nicola Ehlken; Sandra Kreuscher; Stefanie Ghofrani; Marius M Hoeper; Michael Halank; F Joachim Meyer; Gabriele Karger; Jan Buss; Jana Juenger; Nicole Holzapfel; Christian Opitz; Jörg Winkler; Felix F J Herth; Heinrike Wilkens; Hugo A Katus; Horst Olschewski; Ekkehard Grünig
Journal:  Circulation       Date:  2006-09-18       Impact factor: 29.690

Review 5.  Principles of rehabilitation and reactivation: pulmonary hypertension.

Authors:  Alberto M Marra; Benjamin Egenlauf; Eduardo Bossone; Christina Eichstaedt; Ekkehard Grünig; Nicola Ehlken
Journal:  Respiration       Date:  2015-02-13       Impact factor: 3.580

6.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

Review 7.  Pulmonary rehabilitation exercise prescription in chronic obstructive lung disease: US survey and review of guidelines and clinical practices.

Authors:  Chris Garvey; M Dot Fullwood; Julia Rigler
Journal:  J Cardiopulm Rehabil Prev       Date:  2013 Sep-Oct       Impact factor: 2.081

8.  Measurements of cardiac output during constant exercises: comparison of two non-invasive techniques.

Authors:  N Tordi; L Mourot; B Matusheski; R L Hughson
Journal:  Int J Sports Med       Date:  2004-02       Impact factor: 3.118

9.  Left Ventricular Diastolic Function Assessment of a Heterogeneous Cohort of Pulmonary Arterial Hypertension Patients.

Authors:  Dagmar F Hernandez-Suarez; Francisco R Lopez Menendez; Denada Palm; Angel Lopez-Candales
Journal:  J Clin Med Res       Date:  2017-02-21

10.  The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia.

Authors:  Paul Robach; Jose A L Calbet; Jonas J Thomsen; Robert Boushel; Pascal Mollard; Peter Rasmussen; Carsten Lundby
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  2 in total

Review 1.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

2.  Exercise preconditioning prevents left ventricular dysfunction and remodeling in monocrotaline-induced pulmonary hypertension.

Authors:  Cristine Schmidt; José A Bovolini; Nádia Gonçalves; Francisco Vasques-Nóvoa; Maria do Amparo Andrade; Mário Santos; Adelino Leite-Moreira; Tiago Henriques-Coelho; José Alberto Duarte; Daniel Moreira-Gonçalves
Journal:  Porto Biomed J       Date:  2020-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.